Cervical cancerMACA CANCER INFORMATION GUIDE

Understanding cervical cancer.

What cervical cancer is, how HPV vaccination and screening can prevent it, the signs to look out for, how it is diagnosed and staged, and the treatments your care team may discuss with you.

What is cervical cancer?

Cervical cancer begins when cells in the cervix grow out of control and form a tumour. It usually develops slowly, over many years, from abnormal cells known as pre-cancer. This is why it is one of the most preventable cancers: pre-cancer can be found by screening and treated before it ever becomes cancer.

Where the cervix is

The cervix is the lower, narrow part of the womb (uterus). It connects the womb to the vagina, and opens during childbirth to let the baby through. The outer part of the cervix, which a health worker can see during an examination, is covered by flat cells called squamous cells. The canal that leads up into the womb is lined by gland cells. Most cervical cancers start where these two kinds of cells meet, an area called the transformation zone.

What causes it

Almost all cervical cancers are caused by long-lasting infection with certain types of human papillomavirus (HPV). HPV is a very common virus that is passed on through intimate skin-to-skin and sexual contact. Most people will have HPV at some point in their lives, and in most people the body clears it without any problems. Only when a high-risk type stays in the cervix for many years can it slowly cause changes that may become cancer.

According to the World Health Organization, persistent HPV infection causes about 95% of cervical cancers, and two types, HPV 16 and HPV 18, cause around 76%. It usually takes 15–20 years for abnormal cells to become cancer, but this can happen in 5–10 years in women whose immune system is weakened, for example by untreated HIV.

How common is cervical cancer?

Cervical cancer is the fifth most common cancer in women worldwide. The World Health Organization estimates that about 604,000 women were diagnosed with cervical cancer in 2024 and about 280,000 died from it. It is the leading cause of cancer death in women in 26 countries, mostly in sub-Saharan Africa.

Africa carries a heavy share of this burden. The WHO Regional Office for Africa reports that 18 of the 20 countries with the highest burden of cervical cancer are in the WHO African Region, and that Africa accounted for 23% of the world’s cervical cancer deaths in 2022. In Nigeria, WHO describes cervical cancer as the third most common cancer and the second most frequent cause of cancer death among women aged 15–44.

Signs and symptoms

Pre-cancer and early cervical cancer usually cause no symptoms at all. This is why screening matters, even when you feel well. As the cancer grows, signs can include:

  • Bleeding from the vagina between periods, after sex or after the menopause
  • More vaginal discharge than usual, or discharge that smells unpleasant
  • Pain or discomfort during sex
  • Pain in the pelvis, lower back or legs that does not go away
  • Swelling of one or both legs
  • Weight loss, tiredness and loss of appetite

These symptoms are much more often caused by other conditions, such as infections, but they should always be checked.

Risk factors

Persistent infection with high-risk HPV is the main cause of cervical cancer. HPV is so common that having it says nothing about a person’s character or behaviour; most women who have HPV never develop cancer. Other things can make it harder for the body to clear HPV, or make pre-cancer more likely to progress:

  • HIV: women living with HIV are six times more likely to develop cervical cancer than women without HIV, and pre-cancer can progress faster. Taking HIV treatment as prescribed and having regular screening both help.
  • A weakened immune system for other reasons: such as taking medicines that suppress the immune system after an organ transplant.
  • Smoking: women who smoke are about twice as likely to develop cervical cancer as women who do not. Smoking makes it harder for the immune system to fight HPV.
  • Long-term use of the contraceptive pill: the risk rises slightly with many years of use and falls again after stopping. Talk to your health worker before making any change to your contraception.
  • Pregnancy history: having three or more full-term pregnancies, or a first full-term pregnancy before the age of 20, is linked to a higher risk.
  • Chlamydia: a common sexually transmitted infection that often causes no symptoms and has been linked to a higher risk.
  • Family history: having a mother or sister who has had cervical cancer.
  • Not being screened: women who have never been screened, or not screened for many years, are the most likely to have cervical cancer found at a later stage.

Prevention and screening

Cervical cancer can be prevented. The World Health Organization has a global strategy to eliminate cervical cancer as a public health problem, meaning fewer than 4 new cases a year for every 100,000 women. It rests on three steps, known as the 90–70–90 targets for 2030:

  • 90% of girls fully vaccinated against HPV by the age of 15
  • 70% of women screened with a high-performance test by the age of 35, and again by 45
  • 90% of women with pre-cancer treated, and 90% of women with cervical cancer receiving care

HPV vaccination

The HPV vaccine protects against the HPV types that cause most cervical cancers. It works best when given before a person is ever exposed to HPV, which is why WHO recommends it for girls aged 9–14. It is given as one or two doses, depending on the national schedule. People with a weakened immune system, including those living with HIV, should ideally receive two or three doses. Some countries also vaccinate boys.

In October 2023, Nigeria added the HPV vaccine to its routine immunisation programme. A single dose is offered free of charge to girls aged 9–14 through the National Primary Health Care Development Agency, in schools, communities and health facilities. Ask at your local primary health care centre about vaccination for your daughter.

Screening

Screening looks for HPV or for changes in the cervix in women who have no symptoms, so that pre-cancer can be treated before it turns into cancer. WHO recommends:

  • For most women: regular screening every 5–10 years, starting at the age of 30.
  • For women living with HIV: screening every 3–5 years, starting at the age of 25.

Where regular screening is not yet possible, WHO’s strategy aims for every woman to be screened at least twice in her life, by 35 and again by 45.

Screening tests

  • HPV test: checks a sample from the cervix or vagina for high-risk types of HPV. WHO recommends it as the first-choice screening test, because it prevents more cancers than the other tests. In some places women can take the sample themselves, in private, and self-collected samples are as reliable as those taken by a health worker.
  • Visual inspection with acetic acid (VIA): a health worker applies dilute vinegar to the cervix and looks for areas that turn white, which may be pre-cancer. It is quick, low-cost and widely used in Africa. It is also used to look at the cervix after a positive HPV test.
  • Pap test (cervical cytology): cells are gently brushed from the cervix and looked at under a microscope for abnormal changes.

The tests are usually quick and should not be painful, although you may feel some pressure or brief discomfort. You can ask for a female health worker, and you can ask to have someone with you.

Treating pre-cancer

If screening finds pre-cancer, it can usually be treated simply, sometimes at the same visit. This is called “screen and treat”. Some women, including women living with HIV, may have a further test first to decide who needs treatment. Treatments include:

  • Thermal ablation: a heated probe destroys the abnormal cells.
  • Cryotherapy: a very cold probe freezes and destroys the abnormal cells.
  • LEEP or LLETZ: a thin wire loop heated by an electric current removes the abnormal area. The tissue can then be checked under a microscope.
  • Cone biopsy: a cone-shaped piece of the cervix is removed in a small operation.

After treatment you will be asked to come back for a follow-up test to check that the abnormal cells have gone.

Types of cervical cancer

Cervical cancers are named after the type of cell they start in.

  • Squamous cell carcinoma: starts in the flat squamous cells covering the outer part of the cervix. It is the most common type, making up as many as nine in ten cervical cancers.
  • Adenocarcinoma: starts in the gland cells that line the cervical canal and make mucus. Most other cervical cancers are of this type.
  • Adenosquamous carcinoma: a less common type that has features of both squamous cell carcinoma and adenocarcinoma. It is sometimes called mixed carcinoma.
  • Rare types: other cancers, such as small cell (neuroendocrine) cancers, can occasionally start in the cervix and may be treated differently.

Pre-cancer is not cancer. You may hear it called cervical intraepithelial neoplasia (CIN), dysplasia or a precancerous lesion. Treating it prevents cancer from developing.

Diagnosis

If you have symptoms or an abnormal screening result, your doctor will ask about your health, examine your pelvis and look at your cervix using a speculum, the instrument used during screening. They may then arrange the following tests.

Looking at the cervix

A colposcopy uses a lighted magnifying instrument (a colposcope) to look closely at the cervix after a vinegar solution has been applied to show up abnormal areas. It is done in a clinic and usually takes a few minutes.

Biopsy

A biopsy is the only sure way to diagnose cervical cancer. A sample of tissue is taken and examined under a microscope.

  • Punch biopsy: a small piece of tissue is removed from the cervix, usually during a colposcopy.
  • Endocervical curettage: cells are gently scraped from inside the cervical canal.
  • LEEP or cone biopsy: a larger piece of the cervix is removed. This can be used both to diagnose and to treat pre-cancer or very early cancer.

Checking for spread

If cancer is found, further tests show how far it has spread. These may include an MRI scan of the pelvis, CT or PET-CT scans, an ultrasound, a chest X-ray and blood tests to check your blood count and how well your kidneys and liver are working. Sometimes the doctor looks inside the bladder (cystoscopy) or the bowel (sigmoidoscopy) with a thin camera.

Stages and outlook

The stage describes how far the cancer has grown and spread. Cervical cancer is usually staged using the FIGO system, from stage I to stage IV, with letters and numbers that add more detail.

  • Stage I: the cancer is found in the cervix only. In stage IA it can only be seen under a microscope; in stage IB it is larger and may be visible.
  • Stage II: the cancer has spread beyond the cervix into the upper part of the vagina or the tissue around the womb, but not to the wall of the pelvis.
  • Stage III: the cancer has spread to the lower part of the vagina or to the wall of the pelvis, is blocking the tubes that drain the kidneys, or has reached lymph nodes in the pelvis or abdomen.
  • Stage IV: the cancer has spread into the bladder or rectum (stage IVA) or to other parts of the body, such as the lungs, liver or bones (stage IVB).

Outlook

Cervical cancer can often be cured when it is found early. In the United States, for example, about 91% of women whose cancer is still within the cervix are alive five years after diagnosis, compared with about 62% when it has spread to nearby tissue or lymph nodes and about 20% when it has spread to distant parts of the body. Survival in Africa is lower, mainly because many women are diagnosed late and cannot always reach or complete treatment.

These figures describe large groups of women and cannot tell you what will happen to you. Your care team can talk with you about what your stage and test results mean for you.

Treatment

Treatment depends on the stage of the cancer, its size, your age and general health, whether you would like to have children in the future, and your own preferences. A team that may include gynaecological oncologists, clinical and radiation oncologists, pathologists, radiologists and nurses plans it with you.

Surgery

Surgery is mainly used for early-stage cancer.

  • Cone biopsy: for some very small cancers, removing a cone-shaped piece of the cervix may be enough, and keeps the womb.
  • Radical trachelectomy: removes the cervix and the upper part of the vagina but leaves the womb, so that pregnancy may still be possible. It is an option only for some women with small early cancers.
  • Hysterectomy: removes the womb and cervix. A radical hysterectomy also removes the tissue around the cervix and the upper part of the vagina. Nearby lymph nodes are usually removed or checked at the same time.

Chemoradiation

For cancers that are larger or have spread beyond the cervix (usually stages IB3 to IVA), the main treatment is radiotherapy given together with chemotherapy, called chemoradiation. The chemotherapy, usually a medicine called cisplatin, makes the cancer more sensitive to radiation.

  • External radiotherapy: high-energy rays are aimed at the pelvis from a machine outside the body, usually on weekdays over several weeks.
  • Internal radiotherapy (brachytherapy): a radiation source is placed inside the vagina and cervix for a short time, to give a high dose directly to the tumour. It is an important part of curative treatment.

Treatment for advanced or returning cancer

If the cancer has spread to distant parts of the body, or comes back after treatment, the aim is usually to control it, relieve symptoms and help you live as well as possible. Options include chemotherapy, targeted therapy such as bevacizumab, which cuts off the blood supply the tumour needs to grow, and immunotherapy such as pembrolizumab, which helps the immune system attack the cancer. Radiotherapy can also ease pain and bleeding.

Palliative care

Palliative care focuses on relieving pain and other symptoms and supporting you and your family. It can be given alongside treatment at any stage, not only at the end of life.

Clinical trials

Clinical trials are research studies that test whether a new treatment, a new combination of treatments or a new way of giving an existing treatment works better than current care. Many of today’s standard treatments were first offered through clinical trials.

What taking part involves

  • Every trial has eligibility criteria, such as the type and stage of cancer, previous treatment and general health.
  • Trials must be approved by a research ethics committee and, for medicines, by the national regulator. In Nigeria this includes NAFDAC and a recognised health research ethics committee.
  • You will be given written information and asked for your informed consent before you join. You can ask questions at any time.
  • Taking part is voluntary. You can leave a trial at any point and still receive standard care.

Finding a trial

Your treating team is the best place to start, because they know your diagnosis and which trials could suit you. Trial registries list studies that are recruiting:

  • Pan African Clinical Trials Registry (PACTR): trials taking place in African countries.
  • WHO International Clinical Trials Registry Platform: one search across registries worldwide.
  • ClinicalTrials.gov: a large international registry run by the US National Library of Medicine.

Living with and after treatment

Side effects

Side effects depend on the treatment and many improve once it ends. Some can last longer, so tell your care team about any that trouble you. They may include:

  • Tiredness, nausea and a higher risk of infection during chemotherapy
  • Diarrhoea, needing to pass urine more often and sore skin in the pelvic area during radiotherapy
  • Narrowing, dryness or shortening of the vagina after radiotherapy or surgery, which can make sex and examinations uncomfortable. Your team may suggest a vaginal dilator and lubricants to help
  • Early menopause, with hot flushes and other symptoms, if the ovaries are removed or affected by radiation
  • Swelling of the legs (lymphoedema) after lymph nodes are removed or treated with radiotherapy
  • Loss of fertility. If you may want children in the future, ask about this before treatment starts

Follow-up

After treatment you will have regular check-ups, often every 3–4 months for the first two years and then less often. Report any vaginal bleeding or discharge, pain in the pelvis, back or legs, leg swelling, changes in passing urine or opening your bowels, a cough or unusual tiredness between appointments.

Sex and relationships

Many women worry about sex and intimacy after cervical cancer. Cervical cancer cannot be passed to a partner. When it is safe to have sex again varies, so ask your care team. Talking openly with your partner and your team can help, and there are often practical solutions to problems such as dryness or pain.

Emotional support

A cervical cancer diagnosis can bring fear, stigma and questions from others, and can affect your body image, relationships, work and finances. Remember that HPV is extremely common and that cervical cancer is not anyone’s fault. Talking with family, friends, your care team, a counsellor or other survivors can help.

Questions to ask your care team

  • What type of cervical cancer do I have, and what stage is it?
  • What are my treatment options, and what is the aim of each one?
  • Will I need surgery, chemoradiation or both? Where can I get radiotherapy and brachytherapy?
  • How might treatment affect my fertility, my periods and the menopause?
  • How might treatment affect sex and my relationship, and what can help?
  • What side effects should I expect, and who do I contact if I have them?
  • Should my daughters be vaccinated against HPV, and should my sisters and other women in my family be screened?
  • Is there a clinical trial that could be right for me?

LET’S KEEP THE CONVERSATION GOING

Understanding grows
when we come together.

Connect with MACA